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The role of signaling pathways in the regulation of cellular
ironmetabolism is becoming increasingly recognized. Iron che-
lation is used for the treatment of iron overload but also as a
potential strategy for cancer therapy, because iron depletion
results in cell cycle arrest and apoptosis. This study examined
potential signaling pathways affected by iron depletion induced
by desferrioxamine (DFO) or di-2-pyridylketone-4,4-dimethyl-
3-thiosemicarbazone (Dp44mT). Both chelators affectedmulti-
ple molecules in the mitogen-activated protein kinase (MAPK)
pathway, including a number of dual specificity phosphatases
that directly de-phosphorylate MAPKs. Examination of the
phosphorylation of major MAPKs revealed that DFO and
Dp44mT markedly increased phosphorylation of stress-acti-
vated protein kinases, JNK and p38, without significantly affect-
ing the extracellular signal-regulated kinase (ERK). Redox-inac-
tive DFO-iron complexes did not affect phosphorylation of JNK
or p38, whereas the redox-active Dp44mT-iron complex signif-
icantly increased the phosphorylation of these kinases similarly
to Dp44mT alone. Iron or N-acetylcysteine supplementation
reversed Dp44mT-induced up-regulation of phospho-JNK, but
only ironwas able to reverse the effect ofDFOon JNK. Both iron
chelators significantly reduced ASK1-thioredoxin complex for-
mation, resulting in the increased phosphorylation of ASK1,
which activates the JNK and p38 pathways. Thus, dissociation of
ASK1 could serve as an important signal for the phosphoryla-
tion of JNK and p38 activation observed after iron chelation.
Phosphorylation of JNK and p38 likely play an important role in
mediating the cell cycle arrest and apoptosis induced by iron
depletion.
Complex signaling pathways play crucial functions in many
cellular processes, and recently, the role of signal transduction
pathways in iron metabolism has been described (1, 2). For
instance, one of these include the recently established role for
the bone morphogenetic protein-Smad signaling pathway in
the regulation of hepcidin, the hormone of ironmetabolism (3).
Iron is critical for cellular proliferation, and its depletion
results in cell cycle arrest and apoptosis (4–6). As a result, iron
chelation is a promising strategy for cancer therapy (7, 8). Awell
known iron chelator that is clinically used for the treatment of
iron-overload disease is desferrioxamine (DFO)3 (Fig. 1A) (7, 8).
It has also been demonstrated that DFO possesses anti-prolif-
erative activity, with the chelator having entered clinical trials
for cancer treatment (7, 9, 10). However, the efficacy of DFO is
limited by its low lipophilicity andmembrane permeability (11,
12), and hence, other iron chelators with improved lipophilicity
have been developed (8). One such chelator is di-2-pyridylk-
etone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) (Fig. 1A),
which showed marked membrane permeability and pro-
nounced anti-cancer activity against multiple human and
rodent tumor xenograft models (13, 14).
The cytotoxicity of iron chelators can be attributed to their
ability to cause cell cycle arrest and apoptosis due to iron deple-
tion. DFO mainly arrests cells at the G1/S (15–17) phase of the
cycle and has been shown to induce apoptosis in multiple cell
types (16, 18). Inhibition of cell cycle progression is also
reflected by the effect of DFO on cell cycle-related molecules,
particularly decreasing the protein levels of cyclin D1 and to
lesser extent, cyclin A and B1 (19, 20). The expression of cyclin-
dependent kinase 2 (cdk2) is also decreased (19). In addition,
DFO also affects gene expression mediated by transcription
factors, such as hypoxia-inducible factor-1 (HIF-1) and p53
(21).
The chelator, Dp44mT has a much higher anti-proliferative
efficacy thanDFO andwas shown to reduce progression of cells
through the G1/S and G2/M phases of the cell cycle (22). More-
over, Dp44mT was shown to mediate the mitochondrial apo-
ptotic pathway by significantly increasing caspases-3, -8, and -9
protein levels and activities (13). Tumor xenografts taken
fromDp44mT-treatedmice demonstrated increased apoptosis
and up-regulation of the tumor growth andmetastasis suppres-
sor, N-myc downstream-regulated gene-1 (Ndrg1) (13, 14).
Recently, Dp44mT was also shown to selectively inhibit topoi-
somerase II (23). Furthermore, unlike DFO, the iron com-
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plexes of Dp44mT can cause reactive oxygen species (ROS)
generation, which may mediate cytotoxicity (13).
Hence, the anti-cancer activity of iron chelators can be elic-
ited throughmultiplemolecular targets, and the cellular signal-
ing pathways affected by iron depletion remain unclear. Thus,
we examined the molecular targets of these iron chelators and
assessed potential pathways leading to their cytotoxic mecha-
nisms. We performed gene array expression screening after
incubation of cells with DFO or Dp44mT and observed that a
number of signaling pathways were affected after analysis using
bioinformatics resources. Among these pathwayswas themito-
gen-activated protein kinase (MAPK) pathway, which showed
the highest number of genes that were modulated by these
agents.
The MAPKs are evolutionarily conserved kinases that link
extracellular signals to regulate diverse cellular processes,
including cell growth, proliferation, differentiation, migra-
tion, and apoptosis (24, 25). This pathway consists of a core
of three protein kinases, including the extracellular signal-
regulated kinases 1 and 2 (ERK1/2), c-Jun amino-terminal
kinase (JNK), and p38 kinases (24, 25). Generally, JNK
and p38 have anti-proliferative and pro-apoptotic roles,
although ERK1/2 is primarily involved in the proliferative
response (24, 26).
In this study, we demonstrate that iron depletion mediated
by chelators increases the phosphorylation of JNK and p38
MAPKs, as well as the phosphorylation of their downstream
targets, namely p53 andATF-2. Activation of JNK and p38 was,
at least in part, mediated by the apoptosis signal-regulating
kinase 1 (ASK1), aMAP3K, which in turn is activated as a result
of dissociation from its complexation with thioredoxin (Trx)
after iron chelation. These results are important for under-
standing the role of cellular signaling in the response to iron
depletion.
EXPERIMENTAL PROCEDURES
Chelators—Dp44mT was synthesized and characterized
using standard procedures (27, 28). DFO was obtained from
Novartis (Basel, Switzerland).
Cell Culture—The human DMS-53 small cell lung carci-
noma, SK-N-MC, neuroepithelioma, and SK-Mel-28 mela-
noma cell lines were obtained from the American Type Culture
Collection (Manassas, VA). The cells were grown in RPMI 1640
medium by standard procedures, as described previously (29).
Cultures were used when cells were at 80% confluence.
RNA Isolation and Semi-quantitative RT-PCR—Total RNA
was isolated using TRIzol reagent (Invitrogen). Reverse tran-
scriptase-PCR (RT-PCR) was performed using the primers
listed in Table 1, as per standard procedures (30, 31). RT-PCR
was optimized to be semi-quantitative and in the log phase of
amplification. -Actin was used as a loading control, and its
expression was unaltered in all of the treatment conditions
used.
Microarray Processing and Data Analysis—RNA isolation
andmicroarray processing were performed, as described previ-
ously (21, 31). The Affymetrix Human Genome U133 Plus 2.0
430 2.0 array (Affymetrix, Santa Clara, CA) was used, which
assesses 47,000 transcripts from over 38,500 genes.
Initial data analysis for the conversion of images to raw
expression values was performed with Affymetrix Expression
ConsoleTM version 1.1. Three separate arrays were carried out
for each group. Absolute expression signals as well as the mean
probe level fold changes were expressed as SigLogRatio, i.e. log2
of the fold change. To be considered as modulated by the iron
chelators, the intensity value threshold was set at a log2 value of
1 increase or decrease compared with the control, with signifi-
cance at p  0.05, as determined by Student’s t test. Definitive
evidence of differential expression was validated using RT-PCR
assessment using three independent RNA samples. Pathways
were annotated and classified through the DAVID (david.
abcc.ncifcrf.gov; accessed March, 2008) and KEGG pathway
mapping databases (accessed March, 2008). The complete
array dataset can be accessed via theGene ExpressionOmnibus
(www.ncbi.nlm.nih.gov), using GSM662881–GSM662886.
Protein Extraction andWestern Blotting—Protein extraction
and Western blotting were performed using well established
procedures (21, 31). Rabbit anti-human phospho-specific and
nonphospho-specific ERK1/2 (catalog no. 9910 and 4695), JNK
(catalog no. 4668 and 9252), p38 (catalog no. 9215 and 9212),
p53 (catalog no. 9919), ATF-2 (catalog no. 9920), and ASK1
(catalog no. 3761 and 3762) antibodies (Cell Signaling Technol-
ogy, Danvers, MA) were incubated at 1:1000–1:2500 dilutions.
Rabbit anti-human Trx1 antibody (catalog no. 2429, Cell Sig-
naling Technology) was used at a 1:1000 dilution. Mouse
monoclonal anti-human TfR1 (Invitrogen; catalog no. 136800)
was incubated at 1:1000. The secondary antibodies employed
were anti-rabbit and anti-mouse (Sigma), each at a dilution of
1:10,000.As an internal control for protein loading,membranes
were also probed for -actin.
MAPK Phospho-antibody Array—A phospho-specific MAPK
antibody array (Full Moon Biosystems, Sunnyvale, CA) was uti-
lized as described previously (32). This antibody array con-
tained 185 characterized phospho-specific antibodies for pro-
teins in the MAPK pathway and also antibodies for the paired
nonphosphorylated targets to determine the relative level of
phosphorylation. For data analysis, background signals were
removed from all measurements. A ratio was calculated to
measure the extent of protein phosphorylation. Results from
quadruplicate samples were averaged.
Measurement of Glutathione andOxidizedGlutathione—In-
tracellular GSH and oxidized GSH (GSSG) were determined
using the GSH/GSSG ratio assay kit (catalog no. 371757; Calbi-
ochem) according to the manufacturer’s instructions. Briefly,
cells were seeded in 100-mm dishes for experimental treat-
ments. After a 24 h/37 °C incubation with the chelators, the
cells werewashedwith ice-cold PBS and lysed in 50l of PBS by
three freeze-thaw cycles. The lysates were then acidified with
5%metaphosphoric acid, and the supernatant was separated by
centrifugation at 10,000  g for 10 min at 4 °C.
Immunoprecipitation—Immunoprecipitation was per-
formed usingDynabeads proteinG following themanufactur-
er’s procedure (Invitrogen). Briefly, cells were washed with ice-
cold PBS and lysed using Nonidet P-40 lysis buffer (Invitrogen)
containing protease and phosphatase mixture inhibitors
(Roche Diagnostics). Protein (1 mg) was incubated for 2 h/4 °C
with 5 g of monoclonal mouse anti-human thioredoxin anti-
Iron Depletion Activates ASK1, JNK, and p38 Pathways

































body (Abcam, catalog no. ab16845). The mixture was added to
50 l of Dynabeads protein G (Invitrogen) and allowed to
incubate overnight. The beads were washed four times, resus-
pended in SDS-loading buffer, and incubated at 70 °C/10 min.
The supernatant was separated on 4–12% BisTris gel (Invitro-
gen). ASK1 and Trx1 were detected using the rabbit anti-hu-
man antibodies described above (Cell Signaling Technology) at
a 1:1000 dilution.
Densitometry—Densitometric analysis of band intensities
obtained from RT-PCR and Western blotting experiments
were carried out using Quantity One software (Bio-Rad). The
relative intensities of target bands were normalized using the
relative -actin loading control.
Statistical Analysis—Data are expressed asmeans S.E. of at
least three experiments. Experimental data were compared
using Student’s t test and considered statistically significant
when p  0.05.
RESULTS
ChelatorsModulate theMAPKSignaling Pathway—To char-
acterize potential molecular pathways affected by DFO and
Dp44mT, we performed a whole genome microarray screen
after DMS-53 lung carcinoma cells were incubated with DFO
(250 M) or Dp44mT (25 M) over 24 h/37 °C. These chelator
concentrations and this incubation period were used because
we previously demonstrated that under these conditions the
chelators modulate iron-responsive genes (e.g. transferrin
receptor 1 (TfR1) (21, 30)). The higher concentration of DFO
was implemented due to its limited ability to permeate mem-
branes (33, 34). Dp44mT was utilized at a lower concentration
because this ligand shows high permeability and demonstrates
marked iron chelation efficacy and anti-proliferative activity
(13, 14). Initially, the DMS-53 cell type was chosen for these
studies because Dp44mT showed potent anti-tumor efficacy
against this cell type in vitro and in vivo (14).
Incubation of cells with Dp44mT resulted in the alteration
in expression of 1548 genes, whereas DFO affected 731
genes. The majority of affected genes was either of unknown
function or uncharacterized molecular interaction. Conse-
quently, 291 (Dp44mT) and 160 (DFO) genes were success-
fully annotated into known functional categories using the
data base, DAVID.
We identified “cellular processes” and “environmental infor-
mation processing” as the major categories affected by the
chelators, although to a lesser extent “human diseases” and
“metabolism” were also affected (Fig. 1B). Cellular processes
can be further subcategorized into multiple processes, with the
majority of these being involved in “cell communication,”
“immune,” and “endocrine” functions with greater than 20
genes being affected in each of these categories (Fig. 1C). In the
category of environmental information processing, most of the
affected genes were related to “signaling transduction path-
ways,” with 49 and 76 genes altered after incubation with DFO
or Dp44mT, respectively (Fig. 1D). Considering the large num-
ber of genes affected in this category, the effect of DFO or
Dp44mT on signaling pathways was further examined. Both
chelators affected the expression of genes involved in phospha-
tidylinositol, ErbB, calcium, vascular endothelial growth factor
(VEGF), Wnt, and MAPK signaling (Fig. 1E). The alteration of
VEGF signaling is in agreement with the well known effect of
iron depletion on the up-regulation of VEGF expression (35,
36). Incubation of cells with Dp44mT also affected the expres-
sion of the mTOR, Jak-STAT, and TGF--signaling pathways,
although DFO did not. For both chelators, the signaling path-
way that contained the highest number of affected genes was
the MAPK signaling system (DFO, 16 genes, and Dp44mT, 19
genes; Fig. 1E). These results highlighted the potential role of
MAPK signaling in the mechanism of action of these chelators,
and thus, the MAPK signaling transduction pathway was then
further examined.
The expression of MAPK-related genes identified from the
array (Table 2) was confirmed via RT-PCR using the primers
listed in Table 1. The RT-PCR validation confirmed the major-
ity (21 genes) of the results identified from the array (Figs. 2 and
3A), although some genes either showed unchanged expression
or were not reliably detected. Genes up-regulated by both
chelators included CACNB4, DDIT3, EGFR, FGF5, GADD45B,
NFKB1, NFKB2, PDGFA, and PLA2G3 (Fig. 2A). Interestingly,
the expression of PLA2G4A was up-regulated after incubation
with DFO but was down-regulated after Dp44mT. The genes
down-regulated by both chelators included CACNA1E,
CACNA1G, NFATC4, NFATC2, PLA2G12B, TAOK2, and
TGF2 (Fig. 2B).
The gene expression changes confirmed above encompassed
both upstream and downstream targets of the MAPK signaling
pathway. In particular, the upstreammolecules include the fol-
lowing: growth factor-related genes (EGFR, FGF5, and TGF2)
and genes encoding voltage-dependent calcium channels
(CACNB4,CACNA1G, andCACNA1E). The downstream gene
targets include the following: NFKBs, phospholipase A2
(PLA2G3, PLA2G4A, and PLA2G12B), and NFATCs. Both
chelators increased expression of GADD genes, including
DDIT3 (also knownasGADD153) andGADD45B, as consistent
with a previous report from our laboratory that also found
increased GADD45 expression after iron chelation (34).
GADD45B is implicated in the activation of JNK and p38
MAPK (37), whereas GADD153 is downstream and is activated
by the p38 pathway (38). Together, this gene array study
revealed that the MAPK pathway was affected by DFO and
Dp44mT. Considering the critical roles of this pathway in cell
proliferation and apoptosis (24, 25), we examined the effects of
the chelators on the central MAPKs.
Chelators Increase the Phosphorylation of JNK and p38
MAPKs—In addition to the genes above, the array also identi-
fied genes corresponding to MAPK phosphatases (Table 2),
which are also known as dual specificity phosphatases. These
enzymes dephosphorylate threonine and tyrosine residues on
MAPKs (39). The gene array and RT-PCR showed that the dual
specificity phosphatases were significantly (p  0.05) up-regu-
lated to a similar extent by DFO and Dp44mT (Fig. 3A). These
were DUSP5 (2.9-fold)  DUSP1 (1.7-fold)  DUSP16 (1.7-
fold) and DUSP10 (1.3-fold), as determined from RT-PCR.
Recently, other phosphatases have also been shown to be regu-
lated by iron levels resulting in protein hyperphosphorylation
in macrophages (40).
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Although the mRNA expression of MAPK pathway-related
genes was altered, the gene array did not reveal significant
changes in the mRNA expression of major MAPKs, namely
ERK1/2, JNK, and p38. Indeed, using RT-PCR, no significant
alteration in the mRNA expression of these latter kinases was
observed after a 24 h incubationwith eitherDFOorDp44mT at
the same concentrations used in the gene array studies (Fig. 3B).
However, this was not unexpected, as the activation of MAPKs
is governed by their protein phosphorylation state (41), and so
the latter was then examined.
Western blot analysis after incubation with DFO (2.5 or 250
M) or Dp44mT (0.25 or 25 M) demonstrated that the expres-
sion of phospho-ERK1/2 and ERK1/2 protein levels was not
significantly (p  0.05) altered (Fig. 3C). As a positive control,
FIGURE 1. Structures of the chelators used and microarray data showing that DFO and Dp44mT significantly alter the expression of a large number of
genes involved in the MAPK signaling transduction pathway. A, chemical structures of DFO and Dp44mT. B, functional pathway annotation of genes
significantly altered (p  0.05) by DFO (250 M) or Dp44mT (25 M) after a 24 h/37 °C incubation of DMS-53 lung cancer cells as assessed by a human genome
gene array (Affymetrix U133 plus 2.0 array). Only genes with a greater than log2 value of 1.0 as compared with the control were included in the analysis. Genes
in the category of cellular processes (C) and environmental information processing (D) were further sub-categorized according to their functions. E, various
signaling transduction pathways affected. Lists of genes were assessed using DAVID. Pathway annotation was obtained through the public data base, KEGG
pathway mapping.
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incubation of cells with sorbitol (500 mM) was used (42), and
this significantly (p  0.001) increased phospho-ERK1/2
expression. In contrast to ERK1/2, the phosphorylation of the
other MAPKs, JNK and p38, was significantly affected by incu-
bation of the cells with chelators (Fig. 3, D and E). Phosphory-
lation of JNK (JNK1 and JNK2/3 at 46 and 54 kDa, respectively
(43)) wasmarkedly and significantly (p 0.001) increased after
incubation with the highest concentrations of DFO or
Dp44mT, as reflected by the ratio of phospho-JNK/JNK (Fig.
3D). The expression of nonphosphorylated JNK1 (46 kDa (43))
wasmuch stronger in this cell type than the nonphosphorylated
JNK2/3 (54 kDa (43)) in the control and treatment groups (Fig.
3D). Incubation with anisomycin (10 g/ml) was also included
as a positive control, as it is known to increase phosphorylation
of JNK and p38 (44).
The ratio of phospho-p38 to nonphosphorylated p38 was
also significantly (p  0.01) increased even after incubation
with the lower concentrations of DFO (2.5 M) or Dp44mT
(0.25M) (Fig. 3E). Nonphosphorylated p38 expressionwas not
significantly altered after incubation with either of the chela-
tors. Hence, these results showed that both chelators increased
the phosphorylation of JNK and p38 MAPKs but not ERK1/2.
Similar results were also observed in the SK-N-MC neuroepi-
thelioma andSK-Mel-28melanoma cell types (data not shown).
Chelators Affect the Phosphorylation of Other Molecules in
MAPK Signaling—Because protein phosphorylation is crucial
in MAPK signaling (24, 41, 45), we used a phospho-specific
antibody array that focuses on MAPK signaling molecules to
determine whether DFO or Dp44mT affected other MAPK-
related targets. These studies were performed using DMS-53
lung carcinoma cells under the same conditions as the gene
array (i.e. 250 M DFO or 25 M Dp44mT over a 24 h incuba-
tion). Because JNK and p38 were phosphorylated (Fig. 3,D and
E), based on these Western results we were able to calculate a
ratio between phosphorylated and nonphosphorylated forms
and deduce a cutoff ratio for phosphorylation changes in the
antibody array that were likely to be significant. Using a cutoff
ratio of 1.1, we identified 19 and 12 alterations in the expression
of phosphorylated proteins after incubation with DFO or
Dp44mT, respectively (Table 3).
Consistent with the results presented in Fig. 3,D and E, there
was increased expression of phosphorylated JNK (Thr-183 and
Tyr-185) and p38 (Tyr-182) after incubation of cells with either
chelator (Table 3). In addition, the antibody array identified
multiple downstream targets of JNK and p38, which showed an
increase in phosphorylation after incubation with DFO or
Dp44mT (Table 3). Both chelators induced phosphorylation of
p53 (Ser-9, Ser-15, Ser-37, and Thr-18), histone H3.1 (Ser-10),
HSP27 (Ser-15, Ser-78, and Ser-82), and Tau (Ser-356 for DFO
and Ser-396 for Dp44mT). Furthermore, incubation with DFO
increased phosphorylation of p53 at Ser-315, Ser-33, and
Ser-46 and also ATF-2 at Thr-71 or Thr-53. A previous study
also showed that incubation with DFO increased phosphoryla-
tion of p53 at Ser-15 and Ser-20 (46).
Some of these alterations in phosphorylation (i.e. p53; Ser-9,
-15, and -37 and ATF-2; Thr-71 or -53) were confirmed using
Western blot analysis employing specific antibodies for the dif-
ferent phosphorylation sites as shown in Fig. 4. Similar to the
antibody array studies, the Western analysis showed that DFO
(250 M) and Dp44mT (25 M) significantly (p  0.01–0.001)
TABLE 1
List of primers for amplification of human mRNA
F indicates forward, and R indicates reverse.
Pair no. Primer name Accession no. Oligonucleotide (5 to 3) sequence Product size
bp
1 hCACNA1E NM_000721 F-TCTGCCATCTACTTCATTGTG 762
R-CTCCTTGCCTTCTGTCCT
2 hDDIT3 NM_004083 F-GCGTATGTGGGATTGAG 573
R-GCTGGAAGCCTGGTAT
3 hNFATC4 NM_004554 F-GACTGGCTCCAACTTCCTG 565
R-CCCTCCATACGGGTCACTA
4 hNFKB2 NM_001077494 F-GAAGACCTTGCTGCTAAATGC 399
R-TGCTCCACTGACTGGCTCCC
5 hPLA2G3 NM_015715 F-CCCATGTCATTCTACAACCA 537
R-CTAACTTCCCACCTCCTAC
6 hTAOK2 NM_016151 F-AGGTGCGGTTCTTACAGA 327
R-TGCCCACGAAGGAGTT
7 hTGFB2 NM_001135599 F-CTTTCTACAGACCCTACTTCA 642
R-GTATCCATTTCCACCCTA
8 hGADD45B NM_015675 F-CCAGCTACTGCGAAGAAAG 554
R-CTCCCAAGTCCCAAAGTGT
9 hMAPK8 NM_002752 F-TTGACAGACGACGATG 645
R-GACGCCTTATGTAGTGA
10 hMAPK14 NM_001315 F-CCGAGCCAGTCCAAAA 464
R-AGGTGCCCGAGCGTTAC
11 hMAPK1 NM_002745 F-CGTCACTCGGGTCGTA 506
R-CAACCTGCTGCTCAAC
12 hDUSP1 NM_004417 F-TCCCGAATGTGCTGAGTT 552
R-CTGGAGGAAGGGTGTTT
13 hDUSP5 NM_004419 F-TGGTCAGGGAAGGGGTAG 563
R-GCCGTCGCTGTTAGAGGA
14 hDUSP10 NM_007207 F-CACCGTTGTTTAGGTCTTCC 477
R-TACCTCAGCCCATCCC
15 hDUSP16 NM_030640 F-GCCGTCGCTGTTAGAGGA 563
R-TGGTCAGGGAAGGGGTAG
16 hNFKB1 NM_003998 F-TCTTCACTGGGCTGGA 853
R-CGCTTGGGTAACTCTG
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increased the ratio of phospho-p53(Ser-9)/p53, phospho-
p53(Ser-15)/p53, and phospho-p53(Ser-37)/p53 (Fig. 4A). The
ratio of phospho-ATF2 (Thr-71 or -53)/ATF2 was also signifi-
cantly (p  0.001) increased after incubation with DFO (250
M) or Dp44mT (25 M; Fig. 4B). However, the antibody array
did not identify the increase of phospho-ATF2 after incubation
with Dp44mT, because it was below the cutoff ratio used. Incu-
bation with hydroxyurea or anisomycin served as positive con-
trols, as they increase the phosphorylation of p53 and ATF-2,
respectively (47). Although hydroxyurea significantly (p 
0.01) increased the ratio of phospho-p53 (Ser-9)/p53 and (Ser-
15)/p53, it did not have any significant effect on the ratio of
phospho-p53 (Ser 37)/p53 (Fig. 4A).
JNK and p38 kinases play an important role in the activation
of p53 via phosphorylation (48). In particular, phosphorylation
of human p53 at Ser-15 and Ser-37 by both these kinases has
been identified in response to stress stimuli (48), although other
well known kinases, especially ataxia telangiectasia mutated,
can also phosphorylate p53 atmultiple sites uponDNAdamage
(48). Hence, these data suggested that a number of immediate
targets of JNK and p38, such as p53 and ATF2, were phosphor-
ylated after incubation with chelators, indicating the activation
of these kinases. These results further demonstrated the effect
of iron chelation on the MAPK pathway.
Iron Complexes of Dp44mT Increase Phosphorylation of JNK
and p38 Kinases—To understand the importance of iron com-
plexation in theDFO- andDp44mT-mediated phosphorylation
of JNK and p38, DMS-53 cells were incubated for 24 h with the
iron complexes of these ligands. These iron complexes were
generated by pre-complexation of the chelatorwith iron(III) (in
the form of FeCl3). The iron complex of DFOwas prepared in a
1:1 ligand/iron molar ratio at 250 M, because it is a hexaden-
tate ligand, whereas Dp44mT was examined at 1:1 and 2:1
ligand/iron molar ratios (25 and 12.5 M), as it is tridentate (8).
Media containing the relevant concentrations of iron alone (i.e.
12.5, 2,5 and 250M)were also included as controls and showed
that incubation of cells with iron alone (as FeCl3) had no signif-
icant effect on the phosphorylation of JNK or p38 (Fig. 5, A
and B).
After incubation of cells with the DFO-iron complex, the
ratio of phospho-JNK/JNK was significantly (p  0.01) lower
than that found forDFO, resulting in JNKphosphorylation that
was similar to the control (Fig. 5A). In contrast, JNK phosphor-
ylation induced by the Dp44mT-iron (1:1 and 2:1) complexes
remained at a level that was not significantly different than that
of Dp44mT alone. Similarly, studies examining phosphoryla-
tion of p38 showed that the DFO-iron complex significantly
(p  0.01) abolished the DFO-mediated increase in the ratio of
phospho-p38/p38 (Fig. 5B). Conversely, the 1:1 or 2:1
Dp44mT-iron complexes caused a significant (p  0.01)
increase in the ratio of phospho-p38/p38 when compared with
the control, and this was not significantly different than the
effect of Dp44mT alone (Fig. 5B).
These results indicate that the ability of DFO to bind intra-
cellular iron is crucial to mediate phosphorylation of JNK and
p38, as its redox-inert iron complex (8) (which cannot bind
intracellular iron) did not increase phosphorylation of these
kinases. However, Dp44mT-iron complexes were still able to
induce phosphorylation of JNK and p38 kinases. This is likely
due to the pronounced redox activity of Dp44mT-iron com-
plexes that induce ROS generation (13, 27, 49). Hence, in addi-
tion to Dp44mT-binding iron, its redox-active iron complex is
also able to induce phosphorylation of JNK and p38, probably
through the formation of ROS. In fact, various pro-oxidants
FIGURE 2. Validation of MAPK pathway genes identified in the microar-
ray. RT-PCR confirmation of genes that are part of the MAPK pathway from
the microarray analysis as described in Fig. 1 and detailed in Table 2. Shown
are the genes that were up-regulated (A) or down-regulated (B) by either DFO
(250 M) or Dp44mT (25 M) after a 24 h/37 °C incubation with DMS-53 cells.
It should be noted that semi-quantitative RT-PCR may not necessarily reflect
direct fold change in gene expression, but it was used to validate the up- and
down-regulated expression observed in the microarray. RT-PCR panels and
densitometric analysis are from a typical experiment of three performed or
the mean  S.E. of at least three independent experiments, respectively. *,
p  0.05; ***, p  0.001.
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such as H2O2 have been shown to increase JNK and p38 phos-
phorylation (50). It is important to note that the redox-inert
DFO-iron complex possesses no anti-proliferative activity,
whereas the Dp44mT-iron complexes exert anti-proliferative
activity that is similar to that of Dp44mT alone (27). Hence, the
anti-proliferative activity of the chelator-iron complexes or the
chelator itself can be correlated with their ability to induce JNK
and p38 phosphorylation that is known to have anti-prolifera-
tive and pro-apoptotic roles (23, 25).
Iron Supplementation Restores Chelator-induced Phosphor-
ylation of JNK but Not p38—To assess if intracellular iron
depletion by DFO and Dp44mT mediated the increase of JNK
and p38 phosphorylation, we examined the effect of cellular
iron reconstitution using an established protocol implementing
incubation with ferric ammonium citrate ([FAC] 100 g/ml)
(30, 34, 51). In these studies, DMS-53 cells were first incubated
with control media, Dp44mT (25 M), or DFO (250 M) for 24
h/37 °C and then re-incubated with FAC for a further 24
h/37 °C (Fig. 6,A andB). As a positive control for the regulation
of cellular iron levels by chelators and FAC, the expression of
the well characterized iron-regulated molecule, TfR1, was also
assessed (30, 34). As expected, TfR1 expression was signifi-
cantly (p  0.001) increased 3–4-fold after incubation with
DFO (250 M) or Dp44mT (25 M), indicating iron depletion.
FIGURE 3. DFO and Dp44mT increase the expression of MAPK phosphatases and the phosphorylation of JNK and p38. mRNA expression of MAPK
phosphatases, dual specificity phosphatases (DUSP) (identified from the microarray) (A), and MAPKs, ERK1/2, JNK, and p38 (B) in DMS-53 cells after incubation
with DFO (250 M) or Dp44mT (25 M) over 24 h/37 °C. C–E, effect of DFO (2.5 and 250 M) or Dp44mT (0.25 and 25 M) after a 24 h/37 °C incubation of DMS-53
cells on the protein (phosphorylated and nonphosphorylated) expression of MAPKs as follows. C, ERK1/2 (phospho-Thr-202/Tyr-204); D, JNK (phospho-Thr-
183/Tyr-185); and E, p38 (phospho-Thr-180/Tyr-182). Experiments were performed using Western blotting implementing rabbit anti-human phospho-specific
and nonphospho-specific antibodies for ERK1/2, JNK, or p38. Sorbitol (Sor; 500 mM) and anisomycin (Ani; 10 g/ml) were included as positive controls. It should
be noted that semi-quantitative RT-PCR may not necessary reflect direct fold change in gene expression but was used to validate the up- and down-regulated
expression observed in the microarray. Densitometry of phospho- and nonphospho-JNK includes both bands. RT-PCR and Western blot panels are typical
experiments from three performed, and the densitometry is the mean  S.E. of at least three experiments. *, p  0.05; **, p  0.01; ***, p  0.001.
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The chelator-mediated increase in the TfR1 level was then sig-
nificantly (p  0.001) decreased by half after supplementation
of iron using FAC (100 g/ml; data not shown), as we previ-
ously showed using this protocol (30, 34).
Cells incubated with DFO (250 M) or Dp44mT (25 M)
throughout the experiment showed an increase in the phospho-
JNK/JNK ratio relative to cells incubated with control medium
alone (Fig. 6A), which is consistent with the results in Fig. 3D.
When cells were incubated in controlmedium for 24 h and then
incubated with FAC for 24 h, there was no significant change in
the phospho-JNK/JNK ratio as compared with cells incubated
with control medium throughout (Fig. 6A). These data showed
that incubation of control cells with FAC alone did not affect
JNK phosphorylation as the cells were already iron-replete.
However, re-incubation of cells with FAC after the incubation
withDFOorDp44mT significantly (p 0.01) reduced the ratio
of phospho-JNK/JNK to control levels (Fig. 6A). These results
demonstrated that the addition of iron to chelator-treated cells
resulted in diminished JNK phosphorylation and therefore
demonstrated that DFO- or Dp44mT-mediated JNK phosphor-
ylation was due to cellular iron depletion. Interestingly, when
similar iron reconstitution experiments were performed to
study the increased p38 phosphorylation after incubation with
chelators, a different response was observed (Fig. 6B). In this
case, the increase in the phospho-p38/p38 ratio after DFO or
Dp44mT treatment was not reduced after re-incubation with
FAC. This could be interpreted that iron-repletion under the
conditions used did not rescue the increase in p38 phosphory-
lation (Fig. 6B), unlike the effect observed for phospho-JNK
(Fig. 6A). Nevertheless, the ability of DFO to bind intracellular
TABLE 2
Genes in MAPK signaling transduction pathway affected by DFO or Dp44mT
Affymetrix ID Pubmed ID Gene name Gene abbreviation Fold change (log2)a
Altered gene expression due to DFO
209383_at BC003637 DNA damage-inducible transcript 3 DDIT3 2.81
201041_s_at NM_004417 Dual specificity phosphatase 1 DUSP1 2.42
201044_x_at AA530892 Dual specificity phosphatase 1 DUSP1 2.83
221563_at N36770 Dual specificity phosphatase 10 DUSP10 2.15
215501_s_at AK022513 Dual specificity phosphatase 10 DUSP10 2.76
209457_at U16996 Dual specificity phosphatase 5 DUSP5 3.05
211485_s_at AF211188 Fibroblast growth factor 18 FGF18 1.47
231382_at AI798863 Fibroblast growth factor 18 FGF18 1.84
210310_s_at AB016517 Fibroblast growth factor 5 FGF5 1.10
207574_s_at NM_015675 Growth arrest and DNA damage-inducible,  GADD45B 4.25
209305_s_at AF078077 Growth arrest and DNA damage-inducible,  GADD45B 4.10
224542_s_at U43342 Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 2
NFATC2 1.15
205897_at NM_004554 Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 4
NFATC4 1.02
209239_at M55643 Nuclear factor of  light polypeptide gene
enhancer in B-cells 1 (p105)
NFKB1 1.05
209636_at BC002844 Nuclear factor of  light polypeptide gene
enhancer in B-cells 2 (p49/p100)
NFKB2 1.54
224411_at AF349540 Phospholipase A2, group xiib PLA2G12B 1.24
220780_at NM_015715 Phospholipase A2, group iii PLA2G3 1.79
210145_at M68874 Phospholipase A2, group iva (cytosolic, calcium-
dependent)
PLA2G4A 1.10
1555940_a_at BG198711 Protein kinase C,  PRKCA 1.16
209908_s_at BF061658 Transforming growth factor, 2 TGFB2 1.00
1561967_at AI688132 Transforming growth factor, 2 TGFB2 1.01
Altered gene expression due to Dp44mT
244256_at AI912770 Calcium channel, voltage-dependent, 1e subunit CACNA1E 2.26
210380_s_at AF126966 Calcium channel, voltage-dependent, 1g subunit CACNA1G 3.83
207693_at NM_000726 Calcium channel, voltage-dependent, 4 subunit CACNB4 1.10
243244_at H22005 Calcium channel, voltage-dependent, 4 subunit CACNB4 2.14
209383_at BC003637 DNA damage-inducible transcript 3 DDIT3 3.10
215501_s_at GenBank Dual specificity phosphatase 10 DUSP10 2.29
221563_at N36770 Dual specificity phosphatase 10 DUSP10 1.73
1558740_s_at R30807 Dual specificity phosphatase 16 DUSP16 2.24
236511_at AI798976 Dual specificity phosphatase 16 DUSP16 2.55
209457_at U16996 Dual specificity phosphatase 5 DUSP5 3.14
211550_at AF125253 Epidermal growth factor receptor (erythroblastic
leukemia viral (v-erb-b) oncogene homolog,
avian)
EGFR 1.31
207574_s_at NM_015675 Growth arrest and DNA damage-inducible,  GADD45B 4.18
209305_s_at AF078077 growth arrest and DNA damage-inducible,  GADD45B 4.16
238769_at AW450572 MAPK kinase kinase kinase kinase 4 MAP4K4 1.79
238623_at AI633559 MAPK kinase kinase kinase 4 MAPK3K4 3.15
1563367_at BG704389 Microtubule-associated protein  MAPT 2.44
206814_at NM_002506 Nerve growth factor,  polypeptide NGFB 1.29
1556568_a_at N46436 Nemo-like kinase NLK 1.79
216867_s_at X03795 Platelet-derived growth factor  polypeptide PDGFA 1.63
220780_at NM_015715 Phospholipase A2, group iii PLA2G3 2.89
217253_at L37198 Stathmin 1/oncoprotein 18 STMN1 2.20
204986_s_at NM_016151 Tao kinase 2 TAOK2 1.44
209909_s_at M19154 Transforming growth factor, 2 TGFB2 4.67
220407_s_at NM_003238 Transforming growth factor, 2 TGFB2 3.98
228121_at AU145950 Transforming growth factor, 2 TGFB2 4.63
a Data are relative to control.
Iron Depletion Activates ASK1, JNK, and p38 Pathways

































iron was important for its capacity to phosphorylate p38,
because its iron complex did not increase phospho-p38 (Fig.
5B). These results highlight that the chelation-mediated
increase in phospho-JNK and phospho-p38 responds differ-
ently to reconstitution of cellular iron levels. Indeed, the initial
stimulus of iron chelation leads to an increase of phospho-p38
levels that were not restored by iron supplementation.
N-Acetylcysteine Supplementation Reduces the Effect of
Dp44mT-induced Phosphorylation of JNK—Because the
Dp44mT-iron complex is redox-active and increases ROS pro-
duction in cells (13) and also elevates phosphorylation of JNK
and p38 (Fig. 5,A andB), it was important to assesswhether this
latter effect was due to ROS generation. To assess this, a similar
approach to the FAC re-incubation studies performed in Fig. 6,
A and B, was employed, but using NAC (Fig. 6, C and D). This
anti-oxidant increases intracellular glutathione levels that can
quench ROS (52). Indeed, experiments in this study demon-
strated that an incubation for 24 h/37 °C with NAC (5 mM)
significantly (p 0.001) increased cellular GSH levels by 151
5% (three experiments) relative to the control (100%; data not
shown).
When cells were re-incubated with NAC after incubation
with Dp44mT, a significant (p  0.01) reduction of the phos-
pho-JNK/JNK ratio was observed relative to cells re-incubated
with Dp44mT (Fig. 6C). In contrast, re-incubation with NAC
did not significantly reduce DFO-mediated phosphorylation of
JNK. As a control, re-incubation with NAC alone after the ini-
tial incubation with control medium did not affect JNK phos-
phorylation relative to control medium. Similar to the studies
examining phosphorylation of p38 after re-incubation with
FAC (Fig. 6B), re-incubation with NAC after incubation with
either DFO or Dp44mT did not decrease the phospho-p38/p38
ratio to control levels (Fig. 6D). Collectively, these results
showed that Dp44mT-mediated JNK phosphorylation is medi-
ated by both iron depletion and cellular ROS induction,
whereas the response of phospho-p38 to the chelators was
more complex.
Chelator-induced Dissociation of ASK1-Thioredoxin Com-
plex and Phosphorylation of ASK1—The mechanism involved
in the increased phosphorylation of JNK and p38 observed
above after incubation of cells with chelators was important to
elucidate. A pathway known to induce phosphorylation of JNK
TABLE 3
Alteration of protein phosphorylation in the MAPK signaling pathway due to DFO or Dp44mT
Molecule Phospho-site Ratioa Effects of phosphorylation on biological processes (phospho-site)
Increase in phosphorylation due to DFO
ATF2 Thr-71 or -53 1.14 Regulates cell cycle, cell growth, and transcription
c-Kit Tyr-721 1.16 Regulates cell adhesion
FAK Tyr-925 1.12 Regulates apoptosis, cell differentiation, and transcription
Histone H3.1 Ser-10 1.18 Unknown
HSP27 Ser-78 1.12 Cytoskeletal reorganization, regulates apoptosis, and cell cycle
HSP27 Ser-82 1.16 Cytoskeletal reorganization and regulates apoptosis
HSP27 Ser-15 1.19 Cytoskeletal reorganization and regulates apoptosis
IRS-1 Ser-312 1.12 Unknown
p38 MAPK Tyr-182 1.23 Cytoskeletal reorganization, regulates apoptosis, cell adhesion, cell
cycle, motility; dual phosphorylation on Thr-180 and Tyr-182,
which activates the enzyme
p53 Ser-315 1.10 Regulates apoptosis, cell cycle, cell growth, and transcription
p53 Ser-37 1.11 Regulates apoptosis and transcription
p53 Ser-33 1.12 Regulates apoptosis, cell growth, and transcription
p53 Ser-46 1.13 Regulates apoptosis, cell growth, and transcription
p53 Ser-15 1.14 Regulates apoptosis, cell cycle, cell growth, and transcription
p53 Thr-18 1.15 Regulates transcription
p53 Ser-9 1.15 Regulates apoptosis, cell cycle, and transcription
SAPK/JNK Thr-183 1.17 Regulates apoptosis, cell adhesion, and transcription; dual
phosphorylation on Thr-183 and Tyr-185, which activates the
enzyme
SAPK/JNK Tyr-185 1.20 Regulates apoptosis, cell adhesion, and transcription; dual
phosphorylation on Thr-183 and Tyr-185, which activates the
enzyme
Tau Ser-356 1.14 Unknown
Increase in phosphorylation due to Dp44mT
Histone H3.1 Ser-10 1.18 Unknown
HSP27 Ser-15 1.10 Cytoskeletal reorganization and regulates apoptosis
HSP27 Ser-78 1.10 Cytoskeletal reorganization, regulates apoptosis, and cell cycle
HSP27 Ser-82 1.15 Cytoskeletal reorganization and regulates apoptosis
p38 MAPK Tyr-182 1.12 Cytoskeletal reorganization, regulates apoptosis, cell adhesion, cell
cycle, and cell motility; dual phosphorylation on Thr-180 and
Tyr-182, which activates the enzyme
p53 Ser-37 1.10 Regulates apoptosis, cell growth, and transcription
p53 Thr-18 1.11 Regulates transcription
p53 Ser-15 1.12 Regulates apoptosis, cell cycle, cell growth, and transcription
p53 Ser-9 1.13 Regulates apoptosis, cell growth, and transcription
SAPK/JNK Thr-183 1.14 Regulates apoptosis, cell adhesion, transcription; dual
phosphorylation on Thr-183 and Tyr-185, which activates the
enzyme
SAPK/JNK Tyr-185 1.26 Regulates apoptosis, cell adhesion, transcription; dual
phosphorylation on Thr-183 and Tyr-185; which activates the
enzyme
Tau Ser-396 1.14 Unknown
a Data are relative to control.
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and p38 has been shown to occur via ASK1 through activation
of the MAPKK 4/7-JNK- and the MAPKK 3/6-p38-signaling
cascade (45). In healthy cells, ASK1 forms an inactive complex
with Trx, thus inhibiting the activation of this kinase (50, 53).
When oxidation of Trx cysteine residues occur, the ASK1-Trx
complex dissociates (50, 53), leading to the phosphorylation
and activation of ASK1 (50, 53). Our previous studies have
shown that DFO and Dp44mT increase Trx oxidation, as these
chelators reduce the activity of thioredoxin reductase (64).
Hence, we hypothesized that phosphorylation of JNK and p38
after cellular iron depletion could be mediated by ASK1, as the
kinase becomes phosphorylated as a result of its dissociation
from the ASK1-Trx complex (50, 53).
To assess the role of ASK1, we first examined the level of
ASK1 phosphorylation after incubation of DMS-53 cells with
DFO (250M) or Dp44mT (25M) over 24 h/37 °C. The results
showed that DFO or Dp44mT significantly (p  0.01–0.001)
increased the phospho-ASK1/ASK1 ratio to 2.55  0.16- and
2.50 0.16-fold of the control, respectively (Fig. 7A). Iron com-
plexes (1:1 ligand/metal ratio) of DFO and Dp44mT were also
tested. Iron alone at the relevant concentration (25 or 250 M)
used for the formation of the chelator complexes did not have
any significant effect on ASK1 phosphorylation relative to con-
trol. In addition, the DFO-iron complexes did not increase
ASK1 phosphorylation relative to the control, although the
FIGURE 4. Iron chelators increase phosphorylation of p53 and ATF2 that
are downstream targets of JNK and p38 kinases. A, p53 at multiple phos-
phorylation sites; B, ATF2 (Thr-71) that was significantly increased upon incu-
bation of DMS-53 cells with DFO (250 M) or Dp44mT (25 M) over 24 h/37 °C.
These targets were identified using the phospho-MAPK antibody array (Table
3) and validated here by Western blotting. The panels and the densitometric
analysis are typical experiments from three performed or mean  S.E. of at
least three experiments, respectively. *, p  0.05; **, p  0.01; ***, p  0.001.
HU, hydroxyurea; Ani, anisomycin.
FIGURE 5. Effect of chelator-iron complexes on the phosphorylation of
JNK and p38. The expression of JNK (phospho-Thr-183/Tyr-185) (A) and p38
(phospho-Thr-180/Tyr-182) (B) in DMS-53 cells after incubation with either
chelator alone (250 M DFO or 25 M Dp44mT) or chelator-iron(III) complexes
at the same concentrations for 24 h/37 °C. The hexadentate DFO-iron com-
plex was examined at a 1:1 molar ratio (chelator-iron(III) ratio; 250 M). Triden-
tate Dp44mT was assessed at 1:1 molar ratio (chelator/iron(III) ratio; 25 M) or
2:1 molar ratio (chelator/iron(III) ratio; 25:12.5 M). The iron(III) complexes
were pre-formed using ferric chloride (FeCl3). FeCl3 at 12.5, 25, or 250 M was
included as a relevant control as it is a component of the complexes. Western
blotting was performed using rabbit anti-human phospho- and nonphos-
pho-specific antibodies for JNK or p38. Densitometry of phospho- and non-
phospho-JNK includes both bands. The panels and the densitometric analysis
are a typical experiment from three performed or mean  S.E. of at least three
experiments, respectively. **, p  0.01.
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Dp44mT-iron complex caused a slight but not significant
increase in the phospho-ASK1/ASK1 ratio. Thus, as per the
effect of these chelator-iron complexes on JNK and p38 (Fig. 5,
A andB), these results showed that the iron-binding property of
the chelators was important for the increase in ASK1
phosphorylation.
Considering that ASK1 forms a complex with Trx (50, 53),
the expression of the latter was assessed after incubation with
chelators. The ligands DFO, Dp44mT, or their 1:1 iron com-
plexes did not affect the protein expression of Trx in cells (Fig.
7B). To assess if the increase in phospho-ASK1 expression was
due to dissociation of ASK1-Trx, we performed co-immuno-
precipitation to examine the levels of the ASK1-Trx complex
after incubation of DMS-53 cells with DFO (250 M) or
Dp44mT (25M) over 24 h/37 °C.We observed that incubation
with DFO or Dp44mT significantly (p  0.01) reduced the
ASK1-thioredoxin complex to 34  3 and 35  5% (n  4) of
the control, respectively (Fig. 7C). Furthermore, the iron com-
plexes (1:1 ratio) of both chelators were not able to significantly
reduce the level of the ASK1-Trx complex relative to the con-
trol. These results are consistent with the studies on the phos-
phorylation of ASK1 (Fig. 7A). To ensure equal amounts of
thioredoxin were successfully immunoprecipitated from the
cell lysates, Western analysis was performed, and the Trx level
was found to be equal (Fig. 7C). Similar data were also obtained
using the SK-N-MCand SK-Mel-28 cell types (data not shown).
FIGURE 6. Effect of iron or NAC supplementation on the DFO- or Dp44mT-induced phosphorylation of JNK and p38. The expression of JNK (phospho-
Thr-183/Tyr-185) (A) and p38 (phospho-Thr-180/Tyr-182) (B) after DMS-53 cells were incubated (i.e. first incubation) with either DFO (250 M) or Dp44mT (25
M) for 24 h/37 °C and then re-incubated (i.e. second incubation) with either ferric ammonium citrate (100 g/ml), DFO (250 M), or Dp44mT (25 M) for another
24 h/37 °C. The expressions of JNK (phospho-Thr-183/Tyr-185) (C) and p38 (phospho-Thr-180/Tyr-182) (D) after DMS-53 cells were incubated the same way as
in A but using NAC (5 mM) in the second incubation rather than FAC. Western blotting was performed using anti-rabbit phospho- and nonphospho-specific
antibodies for JNK or p38. Densitometry of phospho- and nonphospho-JNK includes both bands. The panels and the densitometric analysis are either a typical
experiment from three performed or the mean  S.E. of at least three experiments, respectively. **, p  0.01.
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Therefore, these results demonstrated that increased phos-
phorylation of JNK and p38 after iron chelation was, at least in
part, mediated by the dissociation of ASK1-Trx and thus the
activation of ASK1.
DISCUSSION
It is increasingly recognized that iron plays roles in cell sig-
naling pathways (1, 2). Because iron chelators induce cell cycle
arrest and apoptosis (4, 6, 22), it was important to examine the
molecular signaling pathways andmechanisms leading to these
processes. In this study, we examined the MAPK pathway
because of the high number of genes altered in this pathway
upon incubation of cells with DFO or Dp44mT. Indeed, our
investigation demonstrated that iron depletion mediated by
chelators increases the phosphorylation of JNK and the p38
MAPKs, as well as the phosphorylation of the downstream tar-
gets of JNK and p38, namely p53 and ATF-2 (48, 54, 55). The
increased phosphorylation of JNK and p38 could be mediated
by ASK1 that was activated as a result of dissociation from its
complex with Trx after iron chelation.
For the first time, our results demonstrate that DFO and
Dp44mT increase phosphorylation of ASK1 as the ASK1-Trx
complex dissociates as a consequence of Trx oxidation after
iron chelation, as summarized in Fig. 7D. Hence, elevated phos-
pho-ASK1 could mediate a signaling cascade leading to
increased phosphorylation of the JNK and p38MAPKpathway.
In addition, the expression of a number of genes in the MAPK
pathway was also affected by DFO and Dp44mT, and these
include DUSP1, DUSP10, and DUSP16, which serve as phos-
phatases that de-phosphorylate JNK and p38. The increased
mRNA expression of these phosphatases can be speculated to
be a counteractive response to the up-regulation of phospho-
JNK and p38. Hyper-phosphorylation of p53 at multiple sites
was also prominent after incubation with DFO orDp44mT and
could be mediated by the JNK and p38 pathways.
The JNK and p38 pathways are largely tumor suppressive
considering their role in apoptosis and cell cycle control (24,
56). Thus, the chelator-mediated phosphorylation of these
molecules may be important upstream mediators of apoptosis.
Indeed, the selective p38 inhibitor, SB203580, has been shown
to suppress DFO-induced apoptosis (57, 58). Furthermore,
these stress-activated protein kinases have also been implicated
in cell cycle regulation (56). Of relevance, p38 is proposed to
induce G1/S arrest through a variety of mechanisms, including
direct activation of p53 phosphorylation, direct stabilization of
p21WAF1/CIP1, and decreased cyclin D1 protein stability (56).
JNK is also known to increase stability of p21WAF1/CIP1 and
phosphorylate p53 (56). Thus, activation of p38 and JNK may
also play a role in iron chelation-induced cell cycle arrest. In
fact, we observed increased phosphorylation of p53 at multiple
sites (Fig. 4A). Previously, iron chelation-induced activation of
p53was shown to occur throughHIF-1-dependent and -inde-
pendent mechanisms (59). Thus, activation of JNK and p38
after incubation with chelators could also lead to p53 activa-
tion, because p53 is the immediate downstream target of these
kinases (56).
Incubation of cells with DFO or Dp44mT also increased
ASK1 phosphorylation (Fig. 7A), which plays a role as an apo-
ptosis-signaling molecule in the MAPK pathway. ASK1 exe-
cutes apoptosis mainly via mitochondrion-dependent caspase
activation (60). Overexpression of wild type ASK1 induces
cytochrome c release from the mitochondrion, which activates
caspase-3 and -9 (60). Our previous studies have shown that
Dp44mT-induced tumor cell apoptosis was mediated through
the release of mitochondrial cytochrome c to the cytosol and
activation of caspase-3, -8, and -9 (13). Hence, phosphorylation
of ASK1 after iron chelation can either promote activation of
JNK and p38 leading to apoptosis and/or directly result in the
apoptosis cascade.
As demonstrated by iron supplementation experiments (Fig.
6A), DFO and Dp44mT-induced cellular iron depletion was an
important factor that activated JNK. These results highlight the
sensitivity of the JNK-signaling pathway toward cellular iron
levels. Furthermore, previous investigations have also shown
that JNK signaling can stimulate ferritin degradation and thus
the level of cellular iron pools (1). These results indicate an
important association between iron metabolism and the JNK-
signaling pathway. It should be noted that previous studies have
examined the effect of DFO on MAPKs and demonstrated
increased phospho-ERK1/2 levels after short incubations of up
to 12 h (61, 62), which may be related to an early response
against stress. Clearly, these latter results are in contrast to the
increased levels of phospho-JNK and -p38 observed in this
study after 24 h, where the anti-proliferative effects of these
pathways are probably involved in the activity of chelators
against tumor cells.
In comparison with DFO, Dp44mT-induced JNK activation
ismediated via iron depletion and the ability of its iron complex
to redox cycle (49), thus promotingROSgeneration (13). This is
shown by the observation that the Dp44mT-iron complex
increased JNK phosphorylation, unlike the redox-inert DFO-
FIGURE 7. Effect of DFO and Dp44mT on phospho-ASK1 and ASK1-Trx complex. A, expression of phospho-ASK1 (Ser-83) and ASK1 in DMS-53 cells after
incubation with either chelator alone (250 M DFO or 25 M Dp44mT) or chelator-iron(III) complexes at 1:1 (chelator/iron) molar ratio as determined by Western
blotting using phospho- and nonphospho-specific antibodies for ASK1. B, expression of Trx in DMS-53 cells after incubation as in A. C, co-immunoprecipitation
(Co-IP) examining the ASK1-Trx interaction as determined in DMS-53 cells after incubation as in A using mouse anti-human Trx antibody. The levels of ASK1 and
Trx in the immunoprecipitates (IP) were determined using rabbit anti-human ASK1 and Trx antibodies. The panels and the densitometric analysis are either a
typical experiment from three performed or the mean  S.E. of at least three experiments, respectively. **, p  0.01; ***, p  0.001. WB, Western blot.
D, schematic summary of the effect of iron chelation on the MAPK signaling transduction pathway. The chelators, DFO and Dp44mT increase phosphorylation
of ASK1 because of the dissociation of the ASK1-Trx complex that is caused by the oxidation of Trx.4 This results in elevation of phospho-ASK1, which can
modulate signaling cascades to increase phosphorylation of JNK and p38. A number of dual specificity phosphatases (DUSPs), including DUSP1, DUSP10, and
DUSP16, which directly de-phosphorylate JNK and p38, were also increased by the chelators. This latter effect could be a counteractive response to the
increased phosphorylation of JNK and p38. Hyperphosphorylation of p53 at multiple sites was also prominent as it is directly targeted by the JNK and p38
pathways. JNK, p38, ASK1, and p53 are pro-apoptotic molecules, and their increased phosphorylation could serve as important signals leading to apoptosis
after iron depletion mediated by chelators.
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iron complex (Fig. 5A) (8). In addition, supplementation of cells
with GSH by incubation with NAC rescued the effect of
Dp44mT on increasing JNK phosphorylation, although NAC
had no effect on the ability of DFO to induce this effect (Fig.
6C). Considering these results, it is of interest that the JNK-
signaling pathway is ROS-sensitive (24). However, unlike JNK
and p38, it remains unclear why the ASK1-Trx complex and
ASK1 phosphorylation were not significantly affected by the
redox-active Dp44mT-iron complex (27, 49), because the
ASK1-Trx complex is also known to be a sensor of redox state
(50). Potentially, this could be explained by the differential
access of these complexes into various cellular compartments,
therefore affecting the response of different molecules.
Considering this study, it is of interest to note that blocking
the p38 pathway using the inhibitor, SB202190, resulted in
reduced total iron uptake in erythroid cells, highlighting the
potential significance of this pathway in affecting iron metabo-
lism (63). Indeed, the alterations in p38 phosphorylation
observed in this study after manipulation of cellular iron status
indicate that this signaling pathway has potential roles in regu-
lating molecules involved in iron metabolism.
In conclusion, this investigation shows for the first time that
iron chelation can modulate the ASK1-Trx-signaling system,
which activates the MAPK signaling pathway by increasing
phosphorylation of JNK and p38 kinases. DFO-induced JNK
phosphorylation is solely reliant on the ability of this chelator to
deplete iron, whereas the effect of Dp44mT can be explained by
both its ability to deplete iron and to generate ROS. Up-regula-
tion of theMAPK signaling pathwaymay play an important role
in mediating the cell cycle arrest and apoptosis induced by iron
depletion.
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